{"id":"NCT01143246","sponsor":"Mallinckrodt","briefTitle":"A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin","officialTitle":"A Multi-Center, Randomized, Placebo-controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Lucassin® (Terlipressin) (The REVERSE Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10-11","primaryCompletion":"2013-02","completion":"2013-05-10","firstPosted":"2010-06-14","resultsPosted":"2022-11-29","lastUpdate":"2022-11-29"},"enrollment":196,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hepatorenal Syndrome"],"interventions":[{"type":"DRUG","name":"Terlipressin","otherNames":["Lucassin®"]},{"type":"DRUG","name":"Placebo","otherNames":["Saline"]}],"arms":[{"label":"Terlipressin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is designed to evaluate the efficacy and safety of intravenous terlipressin versus placebo for the treatment of type 1 hepatorenal syndrome (HRS) in participants receiving standard of care albumin therapy.","primaryOutcome":{"measure":"Percentage of Participants With Confirmed Hepatorenal Syndrome (HRS) Reversal","timeFrame":"within 14 days","effectByArm":[{"arm":"Terlipressin","deltaMin":19.6,"sd":null},{"arm":"Placebo","deltaMin":13.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":73,"countries":["United States","Canada"]},"refs":{"pmids":["40704461","37302573","37143199","36633470","28370090","27464593","26896734"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":62,"n":93},"commonTop":["Abdominal pain","Diarrhoea","Nausea","Hypotension","Dyspnoea"]}}